A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma Read more
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2) Read more
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma Read more
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4) Read more
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma Read more
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma Read more
A Prospective, Non-Interventional, Multinational, Observational Study With Isatuximab In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM) Read more
